Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 07612577

Next Previous
X
Search
Drug Profile

PF 07612577

Alternative Names: Ceftibuten + AVP; CTB + AVP; PF 06264006 + PF 07338233; PF-07612577

Latest Information Update: 09 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Anti-infectives
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Urinary tract infections

Most Recent Events

  • 11 Oct 2024 Pfizer completes the Phase-I clinical trials in Urinary tract infections (In volunteers) in Belgium (PO) (NCT06593054) (EudraCT2023-507117-10-00)
  • 29 Jul 2024 Phase-I clinical trials in Urinary tract infections (In volunteers) in Belgium (PO) (NCT06593054) (EudraCT2023-507117-10-00)
  • 08 Feb 2024 PF 07612577 receives Fast Track designation for Urinary tract infections [PO] (In volunteers) in USA, prior to February 2024 (Pfizer pipeline, February 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top